| INTRODUC TI ON
Chronic constipation is a common, chronic gastrointestinal (GI) condition reportedly affecting 14%-17% of the population. 1, 2 There are three categories of GI motility in patients with chronic constipation: those of healthy volunteers. 5 Pharmacotherapeutic agents, such as stimulant laxatives, induce HAPCs and are potentially beneficial to patients with STC. 6, 7 Elobixibat (PubChem CID: 9939892) is a novel, local-acting, ileal bile acid transporter inhibitor (IBAT, also called apical sodium-dependent bile acid transporter, ASBT), which has been approved in Japan in January 2018. Elobixibat interrupts the enterohepatic circulation of bile acids (BAs), upregulating hepatic BA synthesis. 8 BAs induce secretion of water and electrolytes into the colonic lumen 9 and enhance colonic motility, inducing HAPCs. 10 For patients with chronic constipation, this dual-action agent is more effective than single-action agents, like osmotic agents, secretagogues, or prokinetics. However, no reports have investigated whether elobixibat directly enhances colonic motility, inducing HAPCs.
Elobixibat is a highly potent and selective inhibitor of human, murine, and canine IBAT and ameliorates meat-induced constipation in dogs. 11 As the colons of adult canines and humans are anatomically similar, canine digestive phenomena, such as colonic fermentation and water and electrolyte absorption, are comparable to processes observed in humans, and canine fecal properties and circadian rhythm are similar to those of humans. 12, 13 Thus, the dog is an appropriate animal model to investigate the pharmacological effects of elobixibat.
The aim of this study was to assess GI motility following singledose administration of elobixibat using a canine intestinal telemetry system. Sennoside was administered as a positive control in this model because it induces giant migrating contractions (GMCs), which are known as canine HAPCs.
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| MATERIAL S AND ME THODS
| Animals
Six 10-month-old male beagle dogs (Beijing Marshall Biotechnology Co., Ltd, Beijing, China) were used in this study. The body weight of the dogs ranged from 11.0 to 14.3 kg. All dogs were housed one per cage in a room with light/dark cycle of 12/12-h (lights on at 7:00 AM) and were fed 300 g/dog/day of laboratory chow (DS-A, Oriental Yeast Co., Ltd, Tokyo, Japan Star Medical Inc, Tokyo, Japan) were implanted at the serosal surface from the ileum to the colon. To measure circular muscle con- Medical Inc, Tokyo, Japan). At more than 1 month after surgery, the animals were used to evaluate the GI motility. For each dog, motility data from each GI site were transmitted to a computer via a telemetry system designed to monitor GI function (Analyze II, Star Medical Inc, Japan), thus allowing the recording and analysis of GI motility and behaviors without use of animal restraints. The recorded mechanical activities were assessed using the software for analysis of GI motility.
| Observation of GI motility and behavior
Baseline GI motility was initially measured for more than 20 hours.
This study was started after confirming that there were no data
Key Points
• Bile acids (BAs) are known to enhance colonic motility;
however, no studies have investigated whether elobixibat directly induces motility in the gastrointestinal tract.
• Elobixibat rapidly induced mild giant migrating contractions (GMCs), promoting natural defecation with elevated fecal BAs in conscious dogs implanted with strain gauge force transducers.
• Rapid GMCs induced by elobixibat suggests that it is potentially beneficial for patients with chronic constipation, including slow transit constipation, who have fewer high amplitude propagated contractions with delayed transit time.
acquisition problems as baseline and that the dogs were generally healthy. and dogs in terms of in vitro IBAT inhibition potency. 11, 16 The dose of sennoside was selected according to that previously reported to induce GMC in dogs. [13] [14] [15] Water for injection, adjusted to a pH of 8.5
with NaOH, was used as the vehicle. One hour after administration, the dogs were fed 300 g of laboratory chow. The GI motility effects
were assessed for 10 hours after drug administration. Once defecation occurred, the fecal weight and scale form were determined every 2 hours. The fecal scale form was categorized as normal, soft, or mushy form. Following wet weight determination, each stool sample was mixed for homogeneity to measure fecal BA concentration. A portion of the stool samples was collected, quickly cooled with liquid nitrogen, and stored for BA measurement, whereas the remainder was dried with an automatic dry heat sterilizer (HE-21) for dry-weight quantification. The fecal water content was calculated by subtracting the fecal dry weight from the fecal wet weight, and the weight ratio, with the fecal wet weight, was defined as water weight content. Drug administration was performed using a crossover design, with a washout period of more than 6 days, and vehicle or drug was administered as a single dose. The dogs were monitored with a CCD camera connected to a hard disk video recorder.
| Analysis of GI motility and GMCs during defecation
GI motility was quantified using the analysis software, which calculated the area at each recording site. Aggregated values were obtained for each minute before and after drug administration. The analyzed period began 1 hour before administration and ended 10 hours after administration, with each minute within every hour summed and used as a motility index. GMC was defined as a ≥ 3-fold amplitude increase, relative to baseline, and a confirmed propagated wave. 17 Each maximum amplitude or area of GMC at defecation was individually calculated as the amplitude or area of contraction during GMC, using the analysis software. The GMC index was the summation of the areas of GMC at defecation within 2 and 10 hours after administration. All motility indices, including the amplitude or area of GMC, were analyzed using the same software as described above.
| Total fecal BAs
BA-containing alcohol fractions were collected using a weak alkali treatment, ultrasonic extraction, enzyme treatment, and solid-phase column for the stored canine stools. 18 Using the previously reported LS/ESI-MS/MS method, total fecal BA concentration (µmol g −1 fecal wet weight) was determined by injecting BA-containing alcohol fraction into LCMS 8050 (Shimadzu Corporation; LCMS 8050, Tokyo, Japan) and combining it with a standard product of known concentration. 19 Amount of total fecal BA was calculated by using the data of fecal wet weight and BA concentration. 
| Statistical analysis
| RE SULTS
Each elobixibat group significantly increased defecation frequency during the first 2 hours after administration compared with the vehicle group. Within 10 hours of administration, we observed a significant increase in the total defecation count for the 30 mg kg Typical traces before and after defecation are shown in Figure 3 . GMC, starting from the ascending colon, was observed at the time of all bowel movements in the ascending colon, transverse colon, descending colon, sigmoid colon, and rectum. The mean amplitude in elobixibat groups was similar to that in the vehicle and the mean area mostly within approximate two times F I G U R E 2 Effect of elobixibat on (A and B) total fecal wet weight (g) and (C) water content (%) within 2 or 10 hours after administration. *P < 0.05, **P < 0.01: significant difference between the vehicle group and elobixibat group (Dunnett's multiple comparison test). compared to the vehicle group at each recording site 0-10 hours after administration. Also, no significant differences were found between the elobixibat groups and the vehicle group in GMC index. On the contrary, no significance but a much higher amplitude or area of GMC was observed in the sennoside group. In the transverse colon, a significantly higher GMC index was observed in the sennoside group compared with vehicle group (Table 2) . On the basis of these observations, elobixibat induced mild GMC, similar to the vehicle but not higher than sennoside. There is no differentiation for the extent of propagation among all groups.
In addition, within 10 hours after administration, only transient changes or changes unrelated to the dose were observed in the motility indices of all administration groups, with no clear treatment effects (Figure 4) .
We analyzed the number of defecation, time to first bowel movement, fecal wet weight, fecal water content, the amplitude or for all endpoints.
The total fecal BAs of elobixibat groups are shown in Figure 5 .
The use of 30 mg kg −1 elobixibat significantly increased the amount of total BAs and their concentration within 10 hours after administration, compared with the vehicle group.
The direct correlation between the fecal BA concentration and fecal wet weight or fecal water content is shown in Figure 5 . Both 
| D ISCUSS I ON
Clinical trials in the United States and Japan confirm the clinical utility of elobixibat. 16, 20, 21 However, no previous studies have investigated its pharmacological actions on the GI tract, other than those examining GI transit effects in patients with functional constipation in the United States. 22 This study is the first report on the pharmacological actions of a single administration of elobixibat on defecation, GI motility, and fecal BAs in dogs.
In the present study, initial defecation was observed within 2 hours after administration of elobixibat (3 mg kg −1 or more), and the time to initial defecation was remarkably, and dose-dependently, shortened in comparison with the vehicle. Moreover, our results suggest that bowel movements occurred more quickly following elobixibat than sennoside administration. Elobixibat is a local-acting inhibitor of IBAT, which is located on the apical membrane in the terminal ileum, thereby delivering BAs into the colon, which is responsible for its efficacy. Within 2 hours after administration, elobixibat may attribute to increased BA levels in the colon, which enhanced colonic motility and promoted water secretion into the colon.
9,10
Sennoside reaches the colon and is metabolized by colonic microflora before it can exert a prostaglandin E2 (PGE2)-induced laxative effect. 15 Therefore, the difference in first-onset time between elobixibat and sennoside may be due to differing mechanisms of action.
Additionally, elobixibat increased the fecal water content and led to the production of soft or muddy stools. The mechanism elobixibat is different from that of sennoside, which is known to induce fluid secretion and GMCs in the colon by increasing PGE2 synthesis.
15,23
The increase in fecal water content by sennoside was reproduced in the present study. As previously mentioned, BA promoted water secretion in the colon. 9 On the basis of these findings, it is suggested that increased fecal water content is a result of promoted water secretion by increased BAs into the colon.
HAPC, referred to as GMC in dogs, contributes to defecation and is induced by meals. 17, 24 As diet influences secretion of BAs by the duodenum, preprandial administration of elobixibat effectively inhibits IBAT. In the present study, elobixibat was administered before meals, similar to its clinical use. Furthermore, it is well known that direct administration of BAs into the colon induces HAPCs in humans. 10 The results of the present study suggest that GMCs Previous studies have reported that the colonic transit time in patients with chronic constipation is delayed 26 and that the number and duration of mass movements are significantly reduced in constipated patients than in healthy volunteers. 27 Elobixibat has potential benefits for patients with chronic constipation, including STC, who have fewer HAPCs with delayed transit time.
5
This study has some limitations. First, elobixibat was administered as a single dose. Another limitation was that we used healthy dogs. Future studies must be conducted to confirm the efficacy of elobixibat with multiple doses on GI motility, particularly GMCs, in constipated animal models.
In conclusion, elobixibat rapidly induces mild GMCs, promoting natural defecation in healthy dogs. Elobixibat has potential benefits for patients with chronic constipation, including STC, who have fewer high amplitude contractions with delayed transit time.
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